Previous close | 50.22 |
Open | 49.85 |
Bid | 46.55 |
Ask | 49.00 |
Strike | 120.00 |
Expiry date | 2024-06-21 |
Day's range | 49.85 - 50.25 |
Contract range | N/A |
Volume | |
Open interest | 12 |
AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.